Diabetes Treatments

Carolyn Harris Excerpts

Tuesday 29th October 2024 Westminster Hall

[Carolyn Harris (in the Chair)]

I will call Sarah Bool to move the motion, and then call the Minister to respond. There will not be an opportunity for the Member in charge to wind up, as is the convention.

[Sarah Bool (South Northamptonshire) (Con)]

I beg to move,

That this House has considered diabetes treatments.

It is a pleasure to serve under your chairmanship, Mrs Harris. On 21 May 2021, my world changed forever when I was diagnosed with type 1 diabetes at the age of 33. While my diagnosis was a shock, given its late onset, the feelings of fear, disbelief and sadness are shared by all those diagnosed—young or old, with type 1 or type 2.

Diabetes is a complicated condition that has been done the great disservice of being stigmatised through misunderstanding. It is not necessarily that we have eaten too many sweets or not looked after ourselves. Type 1 is an autoimmune condition—we did nothing to cause it—and people can develop it later in life; Mr Speaker and I can attest to that. Type 2 is not just for the over-40s and the unfit; someone can be slim and active, like Sir Steve Redgrave, and still be diagnosed. That is why I have secured today’s debate. Breaking down the stigma and investing in early treatment of diabetes is so important to allow patients to live fulfilled lives, and to do so in the most long-term, cost-efficient manner for the Government.

Our understanding of how to treat diabetes has come on leaps and bounds since the discovery of insulin back in 1921, but there is still so much more that we can do. Some 5.6 million people in the UK are diagnosed with diabetes. That includes 4,329 people in my constituency of South Northamptonshire—more than 6% of the population. However, last year, just 54% of my constituents with diabetes received all eight of their essential checks, which are important for identifying and preventing complications.

The total cost of diabetes to the NHS is estimated at £10.7 billion, and 60% of that is spent on the costs of diabetes complications. Every week, complications from diabetes lead to 2,990 cases of heart failure, more than 184 amputations, 930 strokes and 660 heart attacks. Those should be preventable with the right education, the right support, and the right attitude from individuals and the Government.

There is so much that I could talk about on diabetes, but this is a short debate, so my initial ask of the Government, on type 1, is that we end the postcode lottery, with equitable treatment for those living with diabetes wherever they live in the UK.

Oral Answers to Questions

Carolyn Harris Excerpts

Tuesday 23rd July 2024 Commons Chamber

[Andrew Gwynne]

I thank the hon. Lady for the way in which the Liberal Democrats approached the issue of health and social care during the election campaign. As my right hon. Friend the Secretary of State has already said, we will work with all in the House who want to fix our broken health and social care system. Of course we will work collegiately across parties, and of course all issues relating to how we fix our broken social care system will be discussed during those cross-party deliberations.

[Carolyn Harris (Neath and Swansea East) (Lab)]

T1. If he will make a statement on his departmental responsibilities.

[The Secretary of State for Health and Social Care (Wes Streeting)]

Our NHS is broken. This Government have been honest about the problems we face because we are serious about fixing them, and we have not wasted a moment. We have appointed Lord Darzi to carry out an independent investigation of the state of our NHS, we are resetting the relationship with junior doctors with negotiations starting today, and we are laying the foundations for the delivery of 40,000 more appointments a week to cut waiting lists. The Gracious Speech kick-started a decade of national renewal, with modernisation of the Mental Health Act as well as the smoking reform, which will ensure that this generation of young people is the first smoke-free generation, and will be the first step towards ensuring that that generation is the healthiest in history.

[Carolyn Harris]

During their free NHS 40-plus health checks, women are assessed for conditions that may affect them as they grow older, but menopause is not included. To include it would be cost-neutral and would not only help millions of women to recognise the symptoms, but prevent needless GP appointments when those symptoms start to develop. Along with Menopause Mandate, I have been campaigning tirelessly on this issue. Will the Secretary of State please look into it as a matter of urgency?

[Wes Streeting]

I am delighted to see my hon. Friend back in the House. She campaigns relentlessly on this vital issue, and it would be very risky for me to do anything other than agree to meet her, because I share her view that progress needs to be made on it.

Leighton Hospital Rebuild

Carolyn Harris Excerpts

Wednesday 28th February 2024 Westminster Hall

[Carolyn Harris (in the Chair)]

I will call Dr Kieran Mullan to move the motion and then the Minister to respond. As is the convention for 30-minute debates, there will not be an opportunity for the Member in charge to wind up.

[Dr Kieran Mullan (Crewe and Nantwich) (Con)]

I beg to move,

That this House has considered the rebuild of Leighton Hospital.

It is a pleasure to serve under your chairmanship, Mrs Harris. My aim today is to take this opportunity to ensure that the rebuild of Leighton Hospital is front and centre of the Minister’s priorities, because a successful rebuild and management of the short-term challenges on the way there are vital to ensuring that my constituents, and residents across the region more broadly, can access excellent healthcare from their local hospital.

All of us involved in the campaign were delighted when we secured Leighton’s place in the £20 billion new hospital programme, which will see 40 hospitals benefit in the largest concerted effort in a generation to modernise our hospital estate. As part of that, Leighton Hospital will receive hundreds of millions of pounds in funding to be rebuilt. The current hospital is a crucial part of our local healthcare services. Built in the early 1970s, Leighton Hospital was opened by the late Queen in 1972. Generations of families have been born there and millions of people have received treatment there, and I know our local community is incredibly proud of its local hospital. Each year, the Mid Cheshire Hospitals NHS Foundation Trust, of which Leighton is the primary site, has more than 100,000 A&E attendances and 290,000 outpatient appointments, and carries out more than 100,000 diagnostic tests. Leighton provides not just healthcare, but over 4,500 job opportunities to members of staff employed at the trust. Those fantastic members of staff cover a whole range of roles, including porters, cooks, receptionists, cleaners, occupational therapists, healthcare assistants, physiotherapists, nurses, doctors and many others.

Having worked in the NHS prior to becoming an MP, I know the difficulties that can arise working in buildings that are in need of refurbishment or, in this case, replacement. The physical infrastructure of the building being worked in is outside the control of the frontline staff, and they often have to do whatever it takes to make it work, but it would be better if they did not have to. Since it was built, Leighton has been expanded with new, modern buildings added on, including a new intensive therapy unit and theatre suite, campaigned for by my hon. and learned Friend the Member for Eddisbury (Edward Timpson) when he represented Crewe and Nantwich.

More recently, I worked with others to secure £15 million for a new A&E department. When it was originally built, much of the building was made with reinforced autoclaved aerated concrete. RAAC is a lightweight, bubbly form of concrete, which was often used in schools, colleges and hospitals from the mid-1960s to the mid-1980s. It is usually found in roofs and occasionally walls and floors, and has since proven to be at risk of structural failure. Since that came to light, it was clear that something needed to be done to ensure that Leighton remains safe for patients.

By the time we started our campaign for a new hospital building, much work had already been done to manage that risk, but it was clear that remedial work would only take us so far and that the best thing to do—not least the better use of taxpayers’ money—was to have a whole new building, so the campaign was launched. Thousands of local residents signed our petition for a rebuild and shared their positive experiences of being treated at Leighton, often having been born there, and they very much wanted to see its future secured. The inclusion of Leighton Hospital in the hospital building programme is a win for its staff and the patients it serves. It has been a privilege to have played a part in securing it, alongside the hard work of so many other key players, including my hon. Friend the Member for Congleton (Fiona Bruce) and my hon. and learned Friend the Member for Eddisbury, and the cross-party support we achieved.

My hon. and learned Friend very much wanted to be here today, but is on an important visit with the Justice Committee. As I know he has done already, I have been glad today to be able to sit down and discuss this important local issue with the excellent Chester South and Eddisbury Conservative candidate for the forthcoming general election, Aphra Brandreth, who is in the Gallery. I know Aphra will continue championing the cause if she is elected as the next MP, which I very much hope she will be.

Having spoken recently with the leadership at Leighton Hospital, I understand that the building programme is coming along well, and I want to thank all those working on the project at Leighton, in NHS England and in the Department of Health and Social Care for their hard work to date. I am delighted that the Leighton site has been selected as the national low-rise hospital 2.0 design template reference site. Procurement of technical advisers is ongoing, and there has been positive engagement with the Cheshire East planning department. The funding allocated for the purchase of the land required to enable a new build has been received, with the purchase expected to be made in the next few weeks. While the trust is waiting for full DHSC and Treasury approval, the current timeline for completion runs through to 2029. That achieves the Government’s goal of ensuring that the proposed projects in the hospital building programme are done before 2030.

However, as with any large infrastructure project, there will always be challenges and room for improvement. Most critically, the RAAC issue has not gone away. The hospital building programme is the long-term solution and we intend to have a whole new hospital to deal with the issue, but in the meantime, remedial works are absolutely necessary to ensure the continued safety of the building.

These challenges can be expected to persist for the next six to seven years. There has been encouraging support to manage them to date, with over £55 million spent in 2022-23 and £28 million in 2023-24, with further spending likely to be needed in the next financial year. A wide range of work has been undertaken, including the construction of a two-storey modular decant ward building. The development provides decant accommodation, which in turn has allowed the trust to undertake essential RAAC refurbishment and stabilisation works to existing wards, ensuring patient safety.

However, the remedial works inevitably create challenges for the dedicated team of staff. Access routes and clinical areas sometimes need to be closed, forcing staff to make large detours and creating a negative impact on the patient and staff experience. It can be difficult to deliver business as usual. Although I appreciate that disruption is at times unavoidable, it would greatly assist the trust if the Minister could talk to colleagues in DHSC and the local NHS to agree a clear, forward-looking timetable for the RAAC work, which will need to carry on and progress as the rebuild does. If there are elements that cannot be agreed in advance, perhaps there could be a smoother mechanism for sign-off to allow more timely decisions to be made.

My second ask is for the Minister to use his considerable skill to work with officials and agree the full cost envelopes and timescales for the whole rebuild as soon as possible, and agree a more streamlined approval process for the elements that are tentatively agreed locally but need sign-off higher up as the work progresses. His attention will benefit the rebuild process not only in Leighton but in other areas if changes can be agreed and implemented across the programme. I am confident that a deep dive by the Minister to understand how it has all been working to date would help identify where improvements in the process could be made.

While I have the Minister’s attention, I want to highlight the potential for Leighton and other NHS hospitals to be heated by deep geothermal resources. A recent study by the British Geological Society identified more than 100 hospitals that sit on deep geothermal resources. As the Minister knows, with a net zero target of 2040, the NHS and hospitals in particular face a considerable challenge to secure net zero heat. I have been working with the Carbon and Energy Fund to develop proposals for identifying the best public sector candidates for deep geothermal, with a focus on NHS sites. I was glad to have the opportunity to meet the Hospitals Minister from the other place, Lord Markham, and his team. We are continuing discussions with them, the Treasury and the Department for Energy Security and Net Zero to see what we might be able to achieve.

I conclude by again paying tribute to all those who were part of the campaign to secure a rebuild of Leighton Hospital, and to all those at the hospital and in the wider NHS who put in an enormous amount of work to secure the progress we have made to date. I know that the Minister will take my questions in the spirit in which they are intended—as positive suggestions as to how we might deliver even more efficient progress—and see what he can do. We remain very happy to have secured the rebuild. We just want to ensure that it is delivered as swiftly as possible, and that Leighton staff and patients are supported to keep on delivering and receiving healthcare within the existing building in the meantime.

Oral Answers to Questions

Carolyn Harris Excerpts

Tuesday 11th July 2023 Commons Chamber

[Maria Caulfield]

I absolutely pay tribute to Tom and to his father. I reassure him that we have many campaigners. Only last week, we received the baton of hope at No. 10 from those campaigning to reduce the number of suicides in this country. We are working on the suicide prevention plan and hope to be able to publish it very soon.

[Carolyn Harris (Swansea East) (Lab)]

14. What steps he is taking to tackle shortages in hormone replacement therapy.

[The Parliamentary Under-Secretary of State for Health and Social Care (Maria Caulfield)]

We continue to engage regularly with our suppliers to prevent and mitigate supply issues in the short term. We have over 70 HRT products. The vast majority are available. We have two that have serious shortage protocols attached to them, but we are hoping to improve supply on those very soon.

[Carolyn Harris]

Although shortages of Utrogestan are ongoing, there is no alternative progesterone product recommended on the serious shortage protocol. Taking oestrogen without progesterone can be dangerous. Provera is a synthetic progesterone alternative to Utrogestan, but it is not included on the HRT prepayment certificate. Will the Minister commit to placing Provera on the list of products covered by the prepayment certificate as a priority and issue a public health warning highlighting the risks of taking oestrogen without progesterone?

[Maria Caulfield]

We are in the process of issuing another bulletin to both GPs and pharmacists on the serious shortage protocols and to make clear the alternatives available. That is a clinical decision. I will certainly look at the issue of Provera because medicines have to tick off a number of criteria to be eligible for the prepayment certificate. I will certainly look into that particular drug on the hon. Lady’s behalf.

Cancer Medicines: Appraisals

Carolyn Harris Excerpts

Tuesday 13th June 2023 Westminster Hall

[Owen Thompson (Midlothian) (SNP)]

It is a pleasure to see you in the Chair, Mrs Harris. I commend the hon. Member for Strangford (Jim Shannon) on securing this important debate. I will do my best to follow the two previous contributions from the hon. Members for Mitcham and Morden (Siobhain McDonagh) and for Chatham and Aylesford (Tracey Crouch) about their personal experience. I cannot contribute to the debate in that way, but I will do what I can.

All our lives have been touched by cancer in one way or another. We all know someone whose life has been changed in some way by the disease. Therefore the appraisal of cancer medicines is of the utmost importance to us all. These medicines give hope and, indeed, life to so many. Yet even something as vital as the evaluation and distribution of cancer medicines did not escape the upheaval of Brexit. The UK ended its membership of the EU three years ago, and that catastrophe, which Scotland did not want, meant that the Medicines and Healthcare products Regulatory Agency withdrew from the European Medicines Agency. While immediate disruption to patient care was avoided, there have been shortages across the board since Brexit.

In Scotland, the Scottish Medicines Consortium—if I mention it again, it will be easier to say SMC—must review and recommend a new medicine before it can be prescribed on the NHS for routine use. This would take place after a medicine has received a marketing authorisation from the MHRA. The SMC advises and provides recommendations to NHS Scotland. This due diligence must be carried out by medical professionals to ensure everyone’s safety. The Scottish Government remain concerned about the effect of Brexit on the authorisation of medicines, as medicines obviously play a crucial role in the NHS. The authorisation and appraisal of medicines also have a key role in the Scottish Government’s commitment to supporting people to live longer, healthier lives. Diagnosing and treating cancer are a priority for the Scottish Government, which is why they are investing £40 million over five years to support cancer services.

However, the NHS in Scotland has finite resources, and medicines are the second largest item of expenditure for NHS Scotland, so difficult choices have to be made. A number of factors need to be looked at. For example, what benefits does the medicine offer compared with other available treatments? Other factors include the quality of life and amount of extra life that may be gained by patients using the new medicine, how the medicine is administered and whether it will save money later on. Those are all examples of the considerations that have to be included when coming to decisions.

Despite UK Government vows to make the MHRA faster and nimbler, we remain concerned about budget and staff cuts to the organisation. There is also a question about the so-called light-touch approach to authorising generic medicines and relying heavily on approvals from larger regulators in the EU and US. The Financial Times reported that the need for cuts at the MHRA has been driven partly by Brexit and the loss of millions of pounds of annual income from its role in authorising medicines in the EU. There has also been a contraction in UK Government funding after the MHRA was subsumed into the budget of the Department of Health and Social Care, as far as I can see.

The hon. Member for Strangford referred to the payback rate of 26%. That is another thing we must not lose sight of. Two very large pharmaceutical companies have already withdrawn from the voluntary scheme as a result of the increase to the rate, which they claim is now punitive. Any further withdrawals from the scheme will surely only have impacts on patients—the people we all want to be doing everything we can to support.

According to recent research by the Nuffield Trust, although the UK Government and pharmaceutical industry averted immediate disruption to patient care from difficulties in the supply of medicines after leaving the single market, there has been a great level of shortages. A review by Imperial College Business School revealed that fewer novel drugs were authorised by the MHRA in 2021—its first year of independence—than by the European Medicines Agency; the UK saw the approval of 35 drugs, compared with 40 in Europe and 52 in the US. That goes back to the points about the availability of medicines and the options that that then makes available to doctors and their patients. Any reform of the regulatory framework must ensure that patients have a voice; their lived experience must inform regulatory decisions. That is where we can all play our part—by relating the experiences that are brought to us.

A cancer diagnosis can be a heartrending and life-changing event, but it can bring positives, and we can all learn from the experiences of those who have gone through it. We need to do everything we can not to add to that heartache by allowing standards to drop or by creating more red tape that stops people getting the medicines they so urgently need.

Brexit casts a long shadow and it has impacted on this area, so we must ensure that there is no withdrawal from the current EU standards or safety controls on medication. It is in all our interests to ensure that we support the development and appraisal of new medicines. We owe that to all our constituents and none more so than those affected by cancer.

[Carolyn Harris (in the Chair)]

I call the shadow Minister.

Eye Health: National Strategy

Carolyn Harris Excerpts

Wednesday 17th May 2023 Westminster Hall

[Marsha De Cordova]

That is exactly the point. Joining up services, which is what my Bill seeks to do, would essentially save the state money, which is crucial.

I have mentioned devolving services and supporting the pathway. When the Minister responds, will he provide an update on where the Government are up to in creating this referral and joined-up pathway system, or EECR, to be specific?

The third area of the strategy would be workforce expansion. There is a significantly uneven distribution of ophthalmology workforces across England, and a quarter of the profession is nearing retirement age. That is extremely concerning, because nearly 80% of eye care units already do not have enough consultants to meet current demand, with over 50% finding it more difficult to recruit for consultant vacancies. In the last year alone, 65% of units had to use locums to fill those consultant vacancies. What do the Government plan to do to respond to this workforce crisis? They say they are bringing forward their plan, but when will it be published?

At the APPG meeting in April, we addressed the challenges of the eye care workforce. Speakers from the Royal College of Ophthalmologists, the College of Optometrists and the Association of Optometrists all made strong recommendations and put forward credible solutions. Again, I would be happy to facilitate a meeting if the Minister is yet to meet those trade bodies. He would hear first hand their strong and credible recommendations, which seek to address some of the workforce challenges.

The Government must make better use of existing workforces while expanding capacity to meet future needs, including by adopting Labour’s call to double medical school places to 15,000 a year. That needs to be complemented with investment in training for wider eye care and multidisciplinary teams and with an expansion in the number of non-medical roles.

The fourth area would be health intelligence and data.  For too long, population data has not been utilised effectively to pinpoint the location of need and the places where opportunities for change can be found. A strategy would solve that by focusing on robust data collection to inform decisions and improve the delivery of service. The UK has no national data to identify people at risk of sight loss. There is potentially a case for looking at how registration for the certificate of vision impairment system works to see whether it could be used to map out an evidence base to show where people with sight loss are living. The lack of data means there is likely to be unmet need in the system, with some people who experience visual impairment not being treated, and some developing conditions that could be avoided if they were treated earlier—as I said earlier, 50% of all sight loss is avoidable.

Without that data, we do not know whether public expenditure on eye health is meeting people’s needs, because that expenditure is not based on any evidence. Where there are still no treatments for certain conditions, the Government should increase spending on eye research, which gets a fraction of the investment it desperately needs. According to UK Research and Innovation, the Government, charities and other public bodies invested £1.4 billion in medical research in 2018, but only 1.5% of that was invested in eye research. To put that in context, only £9.60 was spent on research for each person affected by sight loss in the UK. That is worrying, given that 250 people begin to lose their vision every day.

The fifth area would be improving public awareness. As I said earlier, 2 million people each year turn up to A&E or try to get a GP appointment for a problem that could be dealt with by a community optometrist. A strategy would involve campaigns on the importance of maintaining good eye health, educating the public on the difference between eye screening and eye tests, and improving signposting to where people need to go for help.

England is the only country in the UK without an eye health strategy. Strategies can deliver positive outcomes, as has been the case in Scotland. In England, there are health strategies for other conditions, so why not for eyes? The benefits would transform lives, alleviate pressure on health services and reduce economic costs. Our goal should be to ensure that no one loses their sight unnecessarily. Most people in the Chamber know that I have a condition called nystagmus. I have been living with my sight loss all my life, but those who come to sight loss later in life face even more barriers and challenges.

I would like the Minister to address the following questions. He will get fed up of me saying this, but why will the Government not commit to an eye health strategy for England? Will they appoint a Minister—it could be this Minister—whose sole responsibility is eye healthcare? What are they doing to ensure that every integrated care board has a MECS and that their commissioning is consistent with that of the 23 that already have such services? Five ICBs have no form of MECS provision at all, so what will the Minister do to ensure there is consistency in our communities? When will the Government publish their overdue long-term workforce plan? Will there be a focus on ophthalmology? As I have highlighted, only 1.5% of the £1.4 billion going into medical research involves eyes, so will the Government increase spending on eye health research?

[Carolyn Harris (in the Chair)]

I remind Members that if they wish to speak in the debate, they should bob. I call Dr Rupa Huq.

Oral Answers to Questions

Carolyn Harris Excerpts

Tuesday 1st November 2022 Commons Chamber

[Helen Whately]

I am sure the hon. Member heard the answer I gave a moment ago to a similar question. I absolutely acknowledge the challenge of discharges. The challenge is nothing new, but it has indeed worsened, in part due to the availability of social care. That is one reason why the Government have announced the £500 million discharge fund. I am just a few days into this job—[Interruption.] I am looking at the proposals on how this will—[Interruption.] If she will listen, I am looking to make sure that we allocate that money effectively, because we know that money is tight and we must absolutely make sure that every penny of the funding is well spent on improving the discharge from hospital to people’s homes.

[Carolyn Harris (Swansea East) (Lab)]

10. When he plans to respond to the all-party parliamentary group on menopause’s report on the impact of menopause.

[The Parliamentary Under-Secretary of State for Health and Social Care (Maria Caulfield)]

I am very grateful to the hon. Lady for all her work on issues around the menopause and to all those on the all-party group on menopause for their work. I have read her report and the 13 recommendations. The Government are already working on many of those, from the cost of hormone replacement therapy through to supporting women in the workplace.

[Carolyn Harris]

The lack of information about symptoms is a recognised barrier to diagnosis. As a result, only 14% of the 13 million menopausal women in the UK have a diagnosis and are accessing treatment. More resource, training and awareness are urgently needed. Will the Government listen to the APPG’s recommendations and commit to a menopause-specific health check for all women?

[Maria Caulfield]

The hon. Lady is right about the lack of awareness. Awareness is increasing through her campaign and the campaigns of many others. That is why we are seeing a significant rise in the number of women being prescribed HRT, but there is more work to be done. I am looking through the 13 recommendations from her report, and I am very happy, when we meet regularly, to discuss that further.

World Menopause Day

Carolyn Harris Excerpts

Thursday 27th October 2022 Westminster Hall

[Carolyn Harris (Swansea East) (Lab)]

I beg to move,

That this House has considered World Menopause Day.

It is a pleasure to serve under your chairmanship, Mr Hollobone. I thank the Backbench Business Committee for granting time for this important debate. I am delighted to co-sponsor it with the right hon. Member for Romsey and Southampton North (Caroline Nokes), who shares my passion and determination to improve access to support and treatment for those experiencing symptoms of the menopause.

Anyone in or around Parliament last week might have noticed a buzz of activity. The reason, obviously, was that last Tuesday was World Menopause Day. It was an honour to welcome a group of women who have been instrumental in campaigning for change, from grassroots campaigners to clinicians and celebrities who are using their platform to amplify the message. The day ended with a rally in Old Palace Yard, almost 12 months on from our last Westminster menopause rally. Last year, I stood among jubilant women in Parliament Square. We were celebrating the fact that the Government had listened and committed to dramatically reducing the cost of NHS prescriptions for hormone replacement therapy in England, which would bring them somewhere near the free prescriptions in Wales, Scotland and Northern Ireland. They also committed to setting up a taskforce to look at other barriers women face.

This year, many of the same women were back again. They were as determined as they were last year. They were loud—possibly a little louder than last year. But they were a little less jubilant, a little more sceptical and far less confident in the Government’s commitment to the promises that they made in October 2021. However, they have not given up.

At the rally, Menopause Mandate launched a wonderful book, “It’s Beyond a Joke”, a collection of real lived experience stories from women. Some are graphic, some are funny, but some will break your heart. Every one is an honest account of a woman’s personal menopause journey, and every one is different, because no two women experience the same menopause. There are stories of misdiagnosis, insufficient workplace support and HRT shortages. There are stories from women who are struggling to afford the cost of the menopause, and from women who are hitting brick wall after brick wall when they try to access support. Thankfully, there are stories from women who faced some dreadful experiences but came out the other side—stronger, happier and ready to be their wonderful selves all over again.

[Dr Lisa Cameron (East Kilbride, Strathaven and Lesmahagow) (SNP)]

I thank the hon. Lady for bringing this vital debate to Parliament. Her speech is a wonderful contribution on what so many people have gone through. Does she agree that menopause is not just a physical condition or response in the body, but something with a mental health and wellbeing impact? People need access to specialist services and clinicians, so that their psychosocial needs can be met in a holistic way.

--- Later in debate ---

[Carolyn Harris]

I certainly agree with the hon. Lady. I myself spent eight years on antidepressants, believing that I had mental health problems, only to discover that I was actually menopausal. I can assure everyone that that was a relief.

I urge the Minister, his colleagues and any Member who does not have a copy—copies are available in my office—to read the book, and to join the campaign for change and for better access to menopause care. As I said, it has been almost a year since the first Westminster menopause rally, which followed the introduction of my private Member’s Bill, the Menopause (Support and Services) Bill.

Since then, we have seen a Government in chaos. There have been three different Health Secretaries, but now one has returned. An HRT tsar has come and gone within a few short months, leaving merely a list of recommendations. The HRT stock crisis rumbles on, months after the Department of Health and Social Care promised that it would be resolved. We still await the promised annual prepayment certificate for HRT prescriptions in England. As families up and down the country struggle with the costs of fuel, food and energy continuing to rise at an alarming rate, the prepayment certificate is more important than ever. Choices are being made on where to cut back on household expenses and on which luxuries can go. Menopause is not a choice and HRT is not a luxury but, for many women, the monthly cost of their prescriptions will be one of the casualties of family finance cutbacks. It is therefore vital that the promised prepayment certificate is implemented as soon as possible—women have already waited a year. The latest date we were advised for its introduction was April 2023. I would be grateful if we could have a guarantee from the Minister today that this will not slip any further.

Around the same time as my private Member’s Bill on menopause, the all-party parliamentary group on menopause, which I chair, launched its inquiry into the impact of the menopause. Earlier this month we published our latest report, which highlighted a number of areas where urgent change is vitally needed, including a call for better training for medical professionals. Stories from “It’s Beyond a Joke” show just how much that is needed. One woman says:

“The GP doesn’t want to ‘dabble’ in drugs with me”.

Another writes:

“The GP had no idea…Despite me telling him how much better I felt on HRT, it seemed that he was only concerned with getting me to stop taking it as soon as possible”.

A third shares:

“I spoke to my female GP. Her response when I mentioned the menopause was ‘Well you’re about the right age’. She prescribed antidepressants”.

Evidence taken during the APPG inquiry saw the same pattern of misdiagnosis, ongoing symptoms and repeated appointments with GPs. I am not blaming GPs. At most, they will have had only a few hours’ training on the menopause during medical school, and some will have had none at all. I am pleased that the women’s health strategy commits to changing that, but it really does not go far enough. The women who are suffering now cannot wait seven years for current medical students to enter practice. We need a programme in place to upskill those who are practising and prescribing to support women today and ensure that everyone who needs it has access to accurate and comprehensive information and treatment.

We also need the Government to make resources available to the health service to allow it to provide this training and support to help it to improve its menopause service. Adding menopause to the quality and outcomes framework would also help. Incentivising doctors to improve their knowledge of menopausal symptoms and treatment options would undoubtedly increase levels of diagnosis and, ultimately, benefit patients.

The APPG report also recommends that all women be offered a specific menopause check-up with their GP. Identifying and addressing symptoms early is vital. We know that some women will go through perimenopause and reach menopause early on. For some, this is due to medical treatment or surgical procedures, while for others it is due to a natural decline in their hormones. For a high percentage of women, an appointment in their 40s to discuss symptoms and treatment could be life-changing. Early detection saves women not only months and possibly years of unnecessary pain and anguish, but careers, relationships and lives—it is no coincidence that the suicide rate among women increases by 16% between the ages of 45 and 55.

We also need to look at the postcode lottery that women face in accessing HRT. The stark divide between those who can afford to see a private menopause specialist and those who cannot, coupled with the different products offered as primary treatment options in different parts of the country, results in women from lower socioeconomic communities being far less likely to be able to access the best care. Evidence taken during the APPG inquiry made a clear case for the need for a national formulary, which would allow prescribers across the country to offer their patients a choice of all available HRT products.

Another issue that became a key topic of both the report and the book is support in the workplace. A report published earlier this year by the Fawcett Society found that, shockingly, one in 10 women is leaving the workplace due to a lack of support, with thousands of others reducing hours and avoiding promotion. This trend was echoed in the evidence sessions during the APPG’s inquiry and the stories submitted to the Menopause Mandate book. One woman said:

“I have had to recently step down from my role at work as I’m still not able to perform at the level needed…I tried to keep my chin up and work through, but this failed.”

Another wrote:

“I had to retire early, aged 59, as I simply couldn’t cope anymore. So, I lived in poverty for four years. I had so little money I bought no new underwear until I got my pension. I even stole toilet paper from cafes to make ends meet.”

Another woman said:

“I was dismissed from my job because of my debilitating symptoms…I was told by my employer that I was ‘fabricating an illness’. According to them, I had made it into work and looked fine.”

She was told that there was nothing wrong with her.

Such stories are devastating and, sadly, far too common. Thankfully, we are seeing change, and employers are gradually realising that they need to do more. Just two weeks ago, I hosted an event alongside Swansea City football club for businesses in Swansea to learn more about what their staff are experiencing and what employers can do to help. I was delighted by the turnout and was particularly encouraged by the desire among employers in my city to do so much more. I would love nothing more than for Swansea to be a city that really understands and embraces the menopause, and this week I saw signs of that beginning to happen. I went to watch the football on Sunday—the Swansea-Cardiff derby—and I was astounded by the number of men who came up to me, congratulated me on the work I am doing on the menopause, and asked for selfies to show their wives, so that their wives would be proud that they had spoken to the menopause MP. I hope that translates into votes.

By contrast, I heard of a woman who had gone to see her GP for some help for her symptoms. She was told by her GP, “That Carolyn Harris has a lot to answer for.” Well, perhaps I do, but is it really too much to ask that those who are suffering have access to the best possible care and treatment, and that menopausal women across society are given the attention and respect that they deserve in medical settings, in families and in the workplace? Currently, only a quarter of businesses have menopause support policies in place, but by making simple adjustments, employees will feel valued and, ultimately, businesses will retain loyal and experienced members of staff.

We really are just at that start, and I hope that the Government will sit up and listen and prioritise this area of women’s health. Progress is slowly being made, and the conversations taking place in the media and across communities are wonderful to see, because the more we talk, the more we learn. But it is not enough on its own. Support remains woefully inadequate, which, for 51% of the population, is really not good enough.

Twelve months ago, Government Ministers stood at the Dispatch Box and promised that change was coming. Twelve months ago, women celebrated triumphantly in Parliament Square. Twelve months ago, we all felt that our voices were finally being heard. Twelve months on, our economy is very fragile, families are struggling and menopausal women feel that they have been let down. We cannot keep waiting for the Government to fulfil the promises they have made.

Some colleagues in this Chamber will have been lobbied by their constituents to attend today’s debate. Many will have posted menopause-related content, which I know will have been well received by their constituents, because the menopause revolution is marching on. We are not going away. We are not going to stop asking for what is needed, and we will not be silent. We are not asking for special treatment, and we are not asking to be treated differently. We just want the resource, the respect and the support for women to experience the normality that the menopause can all too often rob them of.

[Mr Philip Hollobone (in the Chair)]

The debate can last until 4.30 pm. I am obliged to call the Front Benchers at no later than 3.57 pm, and the guideline limits are 10 minutes for the Scottish National party, 10 minutes for His Majesty’s Opposition, and 10 minutes for the Minister. Then, Carolyn Harris will have three minutes to sum up the debate at the end. It is Back-Bench time until 3.57 pm and eight Members wish to contribute. There is a strict four-minute limit and I strongly discourage speakers from accepting interventions, because if you do, it means that somebody will drop off the list. If you keep it to four minutes, everybody will get in.

--- Later in debate ---

[Carolyn Harris]

I thank the Minister for his kind words. We have worked together previously and I trust his word—I look forward to the certificate happening in April 2023.

I thank all colleagues for everything they have said. Women out there are listening to this debate, and they are grateful that we are talking about the menopause, because it is talking about it that will make a change.

The hon. Member for Strangford (Jim Shannon) did not enlighten the House about the fact that he is now a local hero, after I mentioned him on “Loose Women” as a male menopause warrior. He has now been elevated to sainthood in Strangford.

We are changing the narrative, and we are changing it by talking—in here, to women, to Ministers and to each other. We have taught so many women about the situation they are in. Who would have thought we would be doing that as MPs? The right hon. Member for Romsey and Southampton North (Caroline Nokes) and I sometimes feel like doctors when we are asked for advice on the menopause. So many people have asked to have that conversation.

I am going to contradict the words of a song written by the male menopause warrior-in-chief, Sir Rod Stewart, that says,

“I don’t wanna talk about it”.

Well, that is wrong, because we do need to talk about it. We should talk about it, and we will talk about it until every one of the 13 million women in this country who are not having the appropriate treatment for the menopause have the respect they deserve and their lives are returned to normal.

Question put and agree to.

Resolved,

That this House has considered World Menopause Day.

Women’s Health Strategy for England

Carolyn Harris Excerpts

Wednesday 20th July 2022 Commons Chamber

[Steve Barclay]

The work on this strategy was done before I arrived in the Department, so it was down to my right hon. Friend and to the Minister of State, my hon. Friend the Member for Lewes (Maria Caulfield). It is great to have this opportunity to pay tribute to my predecessor for all that he did to drive this agenda forward. He is absolutely right about the importance of training and early diagnosis. That is why addressing the issue of fragmented services is so important. As a respondent said, where women raise concerns, they often feel like a lone voice in the wind—that was a phrase in the strategy that really resonated with me. Having hubs, centres of excellence and the ability to look at that data and identify it early, alongside the other initiatives in which he played a major role as Secretary of State, such as the diagnostic hubs, are all a key part of the delivery of this strategy.

[Carolyn Harris (Swansea East) (Lab)]

I rise to speak specifically on the menopause services included in the strategy. As co-chair of the Government menopause taskforce, I broadly welcome the strategy but feel that it falls short in some places.

Although better menopause training for doctors of the future is essential, there is not much in the strategy now in terms of upskilling GPs or prescriber medics, such as pharmacists or women’s health nurses. With only 14% of women accessing hormone replacement therapy and menopause care, through medical lack of awareness in diagnosing and prescribing, training medical professionals of the future does nothing for women today.

With 50% of women not even discussing their symptoms, we need a public awareness campaign—outside the one being run by the media and by grassroots and celebrity activists—to ensure that all women get the memo, as it were. We need a commitment to a national formulary for HRT to end postcode lottery in quality, quantity and availability of body identical hormone replacement therapy—I emphasise body identical.

As for HRT costs, I am delighted that my private Member’s Bill that I negotiated with the Government last October now appears as part of the strategy, but I am bitterly disappointed that the timeframe for that once annual charge is delayed until April 2023— 18 months after it was promised—demonstrating to me a lack of urgency in dealing with women’s health issues that affect 51% of the population.

As we are talking about delays and women not being listened to, I am still waiting on responses to six letters to either this Secretary of State or to his predecessor dating back to 5 May asking to discuss all the issues that I have raised today. I would be grateful to have a meeting to discuss them further.

[Steve Barclay]

The hon. Lady says that she is not being listened to, but my understanding is that she is co-chair of the menopause taskforce, which has been set up to look at these issues. Indeed, she has also had meetings with officials on the subject of HRT. It is slightly remiss of her to suggest that she is not being listened to when Health Department officials are meeting with her and when we have a taskforce under way. There is much consensus around the points that she raises. She has highlighted, quite rightly, the importance of HRT, and we have acted on that. Part of the reason for the delay until April is that the IT systems need to be put in place. I well recall, when I was a Treasury Minister, being asked to move at pace in response to covid, because of the cash-flow pressures on businesses, and sometimes having the same colleagues complaining that forward controls and other issues had not been put in place. We need to put the right IT in place. We will do that for April, and the work is under way. The issues that she raises are being addressed, but in an effective way.

As I said to the shadow Secretary of State, we will work with the royal colleges to address the issue of training. It is a perfectly fair point, and I do not think there is disagreement in the House on that. On the wider issue of addressing disparities, that is exactly what the taskforce is about. That is why we have such a relentless focus on data, why we have a women’s health ambassador to give greater voice to these issues, and why we have brought forward specific measures, such as the family hubs and mobile breast screening units, to better address those disparities.

Menopause

Carolyn Harris Excerpts

Thursday 9th June 2022 Westminster Hall

[Carolyn Harris (Swansea East) (Lab)]

I beg to move,

That this House has considered the menopause.

It is a pleasure to serve under your chairmanship, Mr Robertson. It has been four years since I first spoke in a debate in this place on the menopause. Each year that followed, I duly put my name down to speak in the annual debate on or around World Menopause Day, but it was not enough. While it might have gone some way towards breaking down barriers and lifting the taboo on this great unspoken issue, speaking about the menopause was not doing anything for the millions of women across the country who were suffering the symptoms and in desperate need of help. This issue was something I had a burning desire to champion as I learned more and more about how support and services are failing women across the country, and my opportunity came when I was successful in the private Member’s ballot last year.

The twenty-ninth of October 2021 felt like a momentous day. As we gathered in Parliament Square, there were cheers of joy and tears of relief; the Minister herself was there, so she will know what I mean when I say that you could feel the utter delight in the atmosphere as women celebrated what they perceived as a victory. It is no exaggeration to say that, since that day, I have been bombarded with messages asking when the annual prescription charge for hormone replacement therapy in England will be introduced. We now know—I am sure the Minister will explain the technical reasons for this—that the answer is April 2023: 18 months after the commitment was made, 18 months after the cheers and the tears, and 18 months after that delightful taste of victory, which is so rapidly turning sour.

Naturally, I am frustrated. I have been angry, and I have been very vocal. All the explanations for how and why this has happened mean nothing. They do not help the women who are struggling through a cost of living crisis and can barely afford food and heating, let alone “luxuries” like their medication.

[Kim Leadbeater (Batley and Spen) (Lab)]

As a woman of a certain age, I put on record my personal thanks to my hon. Friend for her tireless campaigning on this important issue and thank her on behalf of many of my family and friends who have repeatedly shared with me their praise and admiration for her work. Does she agree that the menopause is not a minor condition, but can severely impact every part of a woman’s life, and that the only way we can properly support menopausal women is by taking a holistic approach, looking at everything from employment to medicines and mental and physical health, and of course—as my hon. Friend is rightly doing—by keeping this important issue firmly on the agenda?

[Carolyn Harris]

I totally agree with my hon. Friend. As she knows, my passion for this subject means that I will champion every one of the issues she has brought to my attention.

Women such as Brioni say:

“We live in deprived communities where HRT is considered a luxury item. The women I support work part time for minimum wage and on temporary contracts. We simply can’t afford the resources, products, private consultations that other women from more privileged backgrounds can.”

I can testify to the truth of that. I discovered quite early on that my own menopause was menopause, not depression, and when I spoke publicly about it, my friends said to me, “You’re posh having a menopause, Carolyn”—posh, because all the symptoms they were experiencing were things they just put up with and shut up with. I put it under the label of menopause, and the fact that I was able to have HRT—because I went private—made me posh. That was the only time in my life I have ever been called posh.

Brioni is from Doncaster, but what she says is relevant in working-class communities right across the country. Women will always put the needs of their families first, and as long as they have to choose between feeding their kids and paying for their prescriptions, we know where they are going to put their money. To all the Brionis out there struggling, I send my personal apologies that their hopes were prematurely raised. It is not what I expected or wanted, and it is certainly not what I am prepared to accept.

Outside this place, the menopause is a priority, and credit for that must go to all those who are campaigning for change at a grassroots level. Thanks to the willingness of so many of them to work together for the greater good, we now have the menopause mandate in place. We are joining women’s voices into a chorus whose mantra is menopause, menopause, menopause, amplifying the individual voices of grassroots campaigners so that all those individuals and their cases, with all their passions, are brought together in one collective.

[Lilian Greenwood (Nottingham South) (Lab)]

My hon. Friend is making an incredibly powerful speech, and we are all very grateful. One of my constituents, who wrote to me recently, wants to be one of the voices joining my hon. Friend in calling for change. She says:

“I’m tired of worrying about my next prescription. Will I be able to talk to the GP? Can I persuade the receptionist to talk to the GP on my behalf and get them to issue a repeat? Will the prescribed HRT be available? Will the pharmacy leave me guessing and calling daily for updates? Will they eventually admit they can’t get hold of it? I don’t want to feel helpless, anxious, potentially suicidal again. Not when this is easily and cheaply treatable.”

She is right, isn’t she? Those are precisely the problems that we need to sort out.

--- Later in debate ---

[Carolyn Harris]

My sympathy goes to my hon. Friend’s constituent, because the story that she tells is a story that I and other colleagues hear day in, day out from women who are troubled, anxious and scared that they are not getting the treatment or that, if they have the treatment, they cannot get their medication.

I am so proud to work with everyone involved in the menopause mandate, and I am heartened by the work that each and every one of them is doing—whether they are on a national television programme addressing millions of people and spreading the message, or helping a handful of women in their local community. Every one of them is making a difference. We have people such as Davina McCall, Lisa Snowdon, Patsy Kensit, Mariella Frostrup and Gabby Logan. These are strong women with loud voices, who are prepared to share their stories to help support women right across this country to get justice. The right hon. Member for Romsey and Southampton North (Caroline Nokes) and I contribute the political platform for the mandate. We have both made it our mission to mention the menopause in every single policy area right across Whitehall, because it deserves a place at every one of those tables.

Obviously, the Department of Health and Social Care has the biggest role to play when it comes to support and treatment for the physical and psychological impact of the symptoms. It is not just about the prescription charges or the availability of products, because I have grave concerns about the suicide rates among women of menopausal age. There is a 16% increase in risk for this cohort, and there have been some devastating stories in the press recently about women who failed to get a diagnosis and treatment, and who consequently ended their lives. Just a fortnight ago, Penny Lancaster sent me a clip from her local paper about a local solicitor who had taken her life after spending 18 months trying to convince her GP to diagnose her and prescribe her HRT.

However, other Departments have a huge role to play in this endeavour, including the Department for Business, Energy and Industrial Strategy. We have seen women in their 40s and 50s leaving the workplace in growing numbers due to the lack of support. The Department for Work and Pensions deals with the fallout from this, with women suddenly claiming benefits—possibly for the first time in their lives. The Home Office needs to consider the impact that the menopause is having on victims of domestic abuse. We know from research by AVA—Against Violence & Abuse—that domestic abuse escalates when a woman is experiencing menopausal symptoms, and that the symptoms are worse for those who are victims of violent relationships. Education is key if we are to ensure not only that medical professionals are sufficiently trained to diagnose and treat the menopause, but that the next generation are more prepared than any of us were.

Something that really concerns me is the disparity in HRT products currently available in the country. We only have to look at the local formularies to realise that levelling up appears to have overlooked menopausal women. Oxfordshire is recommending the use of newer products, while Manchester’s first-line treatment recommendation is cheap oral medication with synthetic progestogens, with patches reserved for more complex cases, such as those with underlying health conditions. That treatment postcode lottery must be taken seriously. I will continue to campaign for a national formulary, so that all women have fair access to all treatment, regardless of where they live.

Something that came to my attention today, which I am now looking into, is the disparity in the advertising of medications on social media. It is my understanding that on Instagram, medication for erectile dysfunction has free rein to be advertised, but lubricants for vaginal dryness and menopause medications are blocked because they relate to the female genitalia and are therefore assumed to be of a sexual nature. I will be writing to Instagram, and indeed other platforms, to clarify the situation. If that is the case, why are male sexual wellness products given the green light, yet medications for women with menopause are categorised as pornographic? If that is the case, the Department for Digital, Culture, Media and Sport can also expect to hear from me.

At Women and Equalities questions on Wednesday, I raised the issue of menopausal support for women on the prison estate. With 39% of women prisoners aged 40 or over, and 38% aged 30 to 39, I would have assumed that it was vital for a menopause strategy to be in place to provide for those women while they serve their sentences. That is primarily because we know that menopause and perimenopause symptoms affect our physical and mental health, as well as our behaviours.

Next Monday is Menopause Monday, and we are bringing Menopause Mandate to Parliament. All Members will have received invites, but will anyone who has not please let my office know? I encourage everyone to come along to the Jubilee Room and meet the fantastic group of women guests and speakers that we have lined up. I am delighted that, in the afternoon, the Fawcett Society will join us to present its recent report on menopause in the workplace. It is a fantastic piece of work, and many of the areas highlighted as concerns are exactly the same as those that colleagues have mentioned today and that are in the menopause mandate. We will also have clinicians, experts and academics explaining why getting the right treatment and support is so important for both physical and mental health. Finally, we will have women telling their own stories about the barriers they have faced in accessing support and treatment for their symptoms.

When Menopause Mandate was first launched, we invited women to not just sign our petition on the implementation of the single prescription charge, but share their own experiences if they felt able to, and it has been humbling to see how many have done that. I urge colleagues, especially those on the Front Benches, to read the submissions on the website, because they really paint a picture of what some women experience every single day.

Take Lucinda from Kent, who told us about her difficulties in being diagnosed and about the impact of her experience:

“My symptoms started at 41. Three and half years and nine GP appointments later, it was the dentist who first said the word perimenopause to me. By this time my confidence was non-existent, I was unemployable, I was being a terrible parent, a vile and unreasonable housemate, and didn’t think anything would ever improve. I thought about removing myself far too often”—

it was that bad. Lauren told us about the impact on her work:

“I was a senior leader in financial services…but in my early forties I left my job, thinking I had early-onset dementia. I went from being an uber-confident competent leader and the only female in a peer group of 18 men to losing all my self-confidence.”

We also heard from Catherine, who told us about the “painful hell” she descended into after being dismissed by her GP and prescribed anti-anxiety medication:

“I was in so much distress, but I was labelled as a ‘challenging patient’. I felt every subsequent doctor was influenced by this label and that prevented them from doing proper investigations.”

Thankfully, all three women eventually got put on to treatment paths that worked for them. In fact, Lauren says that when her doctor finally diagnosed her, she was the happiest menopausal woman in Bristol. Despite the heartbreaking circumstances those women originally faced, it is encouraging to read their stories and to know that they are now content and able to cope, but there are plenty more out there still living the nightmare that Lucinda, Lauren and Catherine previously experienced.

Women have been denied HRT because their doctors are not properly educated in diagnosing the menopause or in the benefits of the treatment. Women have been prescribed HRT, but struggle with the cost of their prescriptions as they wait for the annual prescription charge. Women who have been given a new lease of life since taking HRT, but who have vivid memories of hot flushes, sleepless nights, brain fog and extreme anxiety, are now terrified of the very real prospect of the symptoms returning due to shortages of the product that literally changed their lives. There are women who cannot take HRT, who need more support, and who feel broken, lost and helpless. We want all those women to be like Lucinda, Lauren and Catherine and to find what works for them. We want them to get the support they need and to be the happiest menopausal women in every town and city up and down this country. That is why we will keep fighting.

One good thing that came out of my private Member’s Bill was the establishment of the menopause taskforce, which I co-chair with the Minister. It brings together decision makers, policy advisers and experts in the field from across the four nations. We can share what works, and what does not, and make joint decisions that will help us all to provide the best possible care and resource for women in future.

I am sure the Minister, the civil servants in the Department of Health and Social Care and the Health Secretary himself have had quite enough of me going on and on about the menopause and the Government’s failure to prioritise this area of women’s health. I know I sound like a broken record—I very often get on my own nerves—but I will not stop, because everyone experiencing symptoms of the menopause deserves more. They deserve fair and equal access to affordable treatment and to be listened to, supported and prioritised. They deserve to be able to carry on their lives once menopause hits.

I wish I could put my arms around every one of those broken and desperate women who have reached out on our website, and even more so around the ones who have not had the chance or the courage to do so. I wish I could tell them that everything will be okay, that the prescription charges and the stock crisis will be sorted and that life will get better. I care passionately about this issue, and I know that there are MPs of all parties right across the House who care passionately too, whether or not they are in this room today.

Mr Speaker himself has pledged his support, and I am delighted to say that on Monday evening he will be signing the Wellbeing of Women menopause workplace pledge, which signals the House of Commons position as a progressive and supportive employer. Employers showing that they understand and support their staff is such a positive step, and I am thrilled that Mr Speaker has embraced that and is leading by example.

We are making progress, albeit slowly, and it would appear that globally the UK is seen as a leader in the field. Since last October, I have heard, as has the Chair of the Women and Equalities Committee, the right hon. Member for Romsey and Southampton North, from the press, politicians and experts from across the world. People expressed a desire to learn from what we are doing—from Australia, Canada, Japan, and across mainland Europe. But if we are going to be the world leaders, we need to get it right ourselves. What is so frustrating is that what is needed to completely change women’s lives is so simple. We need to improve support services and access to treatment and give women’s health the priority it deserves. I know the women’s health strategy is on its way, but it is 2022. Why has it taken until now for women’s health to be prioritised? Some 51% of the population are reliant on this, and they have been left out.

No more delays or false hopes. The time for warm words and gestures has well and truly passed. We cannot let menopausal women today suffer any longer, and we must ensure that future generations do not suffer the same experiences as those who came before them. We need a commitment that this will be a priority, and a promise that it will be taken seriously. We need action, and we need it now.

--- Later in debate ---

[Carolyn Harris]

Thank you, Mr Robertson. I will not take the hour that is left for my summing up, although I could start all over again.

I want to make just a few points. First, I thank everybody for being here and for sharing their personal stories—I am looking in a certain direction. I know it is painful and hard, but when people in this place talk about their personal experiences, it makes us look like what we are—real people with real lives and real feelings—to the outside world. That gives confidence to women out there who are thinking that nobody cares and nobody is listening. Unless we talk to those women, we will not know how they feel. When Nicola Sturgeon appears on “Loose Women” and talks about her menopause, it is inspirational for women right across the UK. When a certain Jim Shannon gets a shout-out as a menopause ambassador on “Loose Women”, it gives confidence to women across the UK that we politicians are listening.

The celebrities who are coming in on Monday are really nervous about coming to Westminster. They think they are coming into a world where they are expected to perform in a particular way, and that we will all be looking at them and thinking, “What do you know about politics?” Through the work they have done, they have proved that they may do politics better than we do, and that they have used their platform to change actually things, without making it party political, which we try not to do on this subject. They are using their platform to share really important messages and really personal stories, in an industry where, traditionally, nobody wants to admit to being a certain age or to potentially being menopausal, because they would be seen as getting on a bit. I really want to thank them.

One thing that it is really important to say is that I would like to see the Davina effect enshrined in legislation—perhaps we can have a show of hands on that—because Davina McCall has played a huge role. I do not think any of us could really have done what we have done without Davina’s documentaries and the work she has done.

[Nickie Aiken]

On that point, rather than having the Davina McCall effect, perhaps we should all write to whomever we are meant to write to, to ask whether Davina McCall should become a Dame.

--- Later in debate ---

[Carolyn Harris]

That is a perfect suggestion, and it is something that has been playing on my mind lately.

[Mr Laurence Robertson (in the Chair)]

Order. This is a winding-up speech and should last only two minutes.

[Carolyn Harris]

Yes, two minutes.

The last thing I will say is that everything that everybody has said is wonderful, but as long as women do not have a single prescription charge, do not have a proper diagnosis and proper medication, are giving up work and do not have equal treatment, we are failing. We cannot continue to fail women.

Question put and agreed to.

Resolved,

That this House has considered the menopause.